AR107300A1 - Método para la preparación de isótopos - Google Patents
Método para la preparación de isótoposInfo
- Publication number
- AR107300A1 AR107300A1 ARP170100024A ARP170100024A AR107300A1 AR 107300 A1 AR107300 A1 AR 107300A1 AR P170100024 A ARP170100024 A AR P170100024A AR P170100024 A ARP170100024 A AR P170100024A AR 107300 A1 AR107300 A1 AR 107300A1
- Authority
- AR
- Argentina
- Prior art keywords
- solution
- exchange resin
- anion exchange
- strong base
- base anion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/04—Processes using organic exchangers
- B01J41/05—Processes using organic exchangers in the strongly basic form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Un método para la purificación de ²²⁷Th a partir de una mezcla que comprende ²²⁷Th y ²²³Ra, comprendiendo dicho método: i) preparar una primera solución que comprende una mezcla de iones ²²⁷Th y ²²³Ra disueltos en una solución acuosa del primer ácido mineral; ii) cargar dicha primera solución en una resina de intercambio aniónico de base fuerte; iii) eluir ²²³Ra de dicha resina de intercambio aniónico de base fuerte utilizando un segundo ácido mineral en una solución acuosa; iv) enjuagar opcionalmente dicha resina de intercambio aniónico de base fuerte utilizando un primer medio acuoso; v) eluir ²²⁷Th de dicha resina de intercambio aniónico de base fuerte utilizando un tercer ácido mineral en una solución acuosa generando así una segunda solución que comprende ²²⁷Th. Se proporciona adicionalmente una solución de ²²⁷Th purificado, una formulación farmacéutica correspondiente y métodos para el tratamiento de enfermedades neoplásicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1600153.9A GB201600153D0 (en) | 2016-01-05 | 2016-01-05 | Isotope preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107300A1 true AR107300A1 (es) | 2018-04-18 |
Family
ID=55406714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100024A AR107300A1 (es) | 2016-01-05 | 2017-01-05 | Método para la preparación de isótopos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10702613B2 (es) |
| EP (1) | EP3400085A1 (es) |
| JP (1) | JP6901498B2 (es) |
| CN (1) | CN108472556B (es) |
| AR (1) | AR107300A1 (es) |
| CA (1) | CA3010191A1 (es) |
| GB (1) | GB201600153D0 (es) |
| TW (1) | TW201726180A (es) |
| UY (1) | UY37067A (es) |
| WO (1) | WO2017118592A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3682959A1 (en) * | 2019-01-16 | 2020-07-22 | Sck Cen | Purification of actinium |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4390517A (en) * | 1979-12-19 | 1983-06-28 | New England Nuclear Corporation | Method, composition and kit for stabilizing radiolabeled compounds |
| US5809394A (en) * | 1996-12-13 | 1998-09-15 | Battelle Memorial Institute | Methods of separating short half-life radionuclides from a mixture of radionuclides |
| NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| EA008195B1 (ru) * | 2003-04-15 | 2007-04-27 | Алгета Ас | Применение тория-227 в лучевой терапии заболеваний мягких тканей |
| US20060228297A1 (en) * | 2003-04-15 | 2006-10-12 | Roy Larsen | Thorium-227 for use in radiotherapy of soft tissue disease |
| JP5687283B2 (ja) * | 2009-12-07 | 2015-03-18 | メディ−フィジックス・インコーポレイテッド | 娘核種を溶出する方法及び溶出を管理するコンピュータプログラム |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201007353D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
| GB201007354D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
-
2016
- 2016-01-05 GB GBGB1600153.9A patent/GB201600153D0/en not_active Ceased
- 2016-12-29 WO PCT/EP2016/082837 patent/WO2017118592A1/en active Application Filing
- 2016-12-29 EP EP16826752.4A patent/EP3400085A1/en not_active Withdrawn
- 2016-12-29 US US16/066,600 patent/US10702613B2/en not_active Expired - Fee Related
- 2016-12-29 JP JP2018553303A patent/JP6901498B2/ja active Active
- 2016-12-29 CA CA3010191A patent/CA3010191A1/en active Pending
- 2016-12-29 CN CN201680077965.8A patent/CN108472556B/zh active Active
-
2017
- 2017-01-05 AR ARP170100024A patent/AR107300A1/es unknown
- 2017-01-05 UY UY0001037067A patent/UY37067A/es not_active Application Discontinuation
- 2017-01-05 TW TW106100235A patent/TW201726180A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108472556B (zh) | 2022-08-02 |
| UY37067A (es) | 2017-08-31 |
| JP2019510809A (ja) | 2019-04-18 |
| EP3400085A1 (en) | 2018-11-14 |
| GB201600153D0 (en) | 2016-02-17 |
| US20190015530A1 (en) | 2019-01-17 |
| CA3010191A1 (en) | 2017-07-13 |
| CN108472556A (zh) | 2018-08-31 |
| WO2017118592A1 (en) | 2017-07-13 |
| TW201726180A (zh) | 2017-08-01 |
| JP6901498B2 (ja) | 2021-07-14 |
| US10702613B2 (en) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000081A (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| BR112017016019A2 (pt) | método para tratamento de câncer, artigo para fabricação, e, kit. | |
| PH12017501125A1 (en) | Radio-pharmaceutical complexes | |
| BR112015025711A2 (pt) | terapia de combinação com ibrutinibe | |
| CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| CL2019001447A1 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| AR112103A1 (es) | Compuestos para el tratamiento de tnbc | |
| AR104060A1 (es) | Partículas de n-(5-ciano-4-((2-metoxietil)amino)piridin-2-il)-7-formil-6-((4-metil-2-oxopiperazin-1-il)metil)-3,4-dihidro-1,8-naftiridina-1(2h)-carboxamida | |
| EA201890282A1 (ru) | Улучшенные ингибиторы простатического специфического мембранного антигена (псма), меченные 18f, и их применение в качестве визуализирующих агентов при раке простаты | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| UY37064A (es) | Método de purificación | |
| MX2015013155A (es) | Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. | |
| CU20190042A7 (es) | Compuestos derivados de naftiridinona | |
| AR107300A1 (es) | Método para la preparación de isótopos | |
| AR107299A1 (es) | Método para la preparación de isótopos | |
| UY37065A (es) | Método de purificación | |
| JOP20170072B1 (ar) | معقدات صيدلية مشعة | |
| BR112018004244A2 (pt) | formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso | |
| AR103267A1 (es) | Método para preparación de liposomas que contienen un ingrediente farmacéutico activo | |
| NZ752287A (en) | Production of re-188/186 particles | |
| EA201600400A1 (ru) | Противоопухолевая фармацевтическая композиция, содержащая темозоломид, и способ ее получения | |
| BR112017008811A2 (pt) | métodos para o tratamento de distúrbios renais | |
| CY1121264T1 (el) | Εστερες στεροειδικης λακταμης και παραγωγα αμφι(2-χλωροαιθυλ)-αμινοφαινοξυ-προπανοϊκου οξεος |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |